MarketCap
Facebook
X
Telegram
Epizyme EBITDA | EPZM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -233 M | -221 M | -176 M | -127 M | -135 M | -110 M | -131 M | -54.3 M | -2.42 M | 79 K | -20.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 79 K | -233 M | -110 M |
Quarterly EBITDA Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -27.2 M | -49.6 M | - | -60.2 M | -55.6 M | -63.1 M | -62.1 M | -51.7 M | -56.2 M | -50.8 M | -57.5 M | -37.3 M | -50.3 M | -30.8 M | -24.3 M | -37.8 M | -29.7 M | -34.6 M | -37.4 M | -36.8 M | -27.6 M | -32.6 M | -35.5 M | -23.6 M | -27.6 M | -22.7 M | -22.3 M | -22 M | -25.1 M | -61.1 M | -15.1 M | -19.2 M | -12.9 M | -6.74 M | 16.3 M | -9.19 M | -1.81 M | -7.3 M | -4.54 M | 4.88 M | 5.1 M | -5.48 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 M | -63.1 M | -29.5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
INmune Bio
INMB
|
-47.3 M | $ 1.43 | -2.05 % | $ 35.4 M |  USA |
 |
Insmed Incorporated
INSM
|
-1.24 B | $ 93.44 | 0.05 % | $ 18.6 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-204 M | $ 43.42 | 1.13 % | $ 6.95 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-54 M | $ 1.47 | -1.64 % | $ 132 M |  France |
 |
Ironwood Pharmaceuticals
IRWD
|
99.6 M | $ 3.49 | 0.87 % | $ 565 M | USA |
 |
Inventiva S.A.
IVA
|
-97.6 M | $ 3.67 | -1.08 % | $ 219 M | France |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-389 M | $ 205.67 | -3.89 % | $ 12.5 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
7.5 B | $ 266.51 | 1.02 % | $ 642 B | USA |
 |
Kamada Ltd.
KMDA
|
26.2 M | $ 7.93 | 2.06 % | $ 457 M |  Israel |
 |
Krystal Biotech
KRYS
|
167 M | $ 313.53 | 0.65 % | $ 9.07 B | USA |
 |
Kura Oncology
KURA
|
-303 M | $ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
-341 M | $ 114.86 | 3.7 % | $ 9.7 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-35.9 M | $ 1.0 | -0.1 % | $ 230 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-10.8 M | $ 31.65 | 7.8 % | $ 1.51 T | France |
 |
Longeveron
LGVN
|
-22.5 M | $ 1.61 | 0.62 % | $ 28.3 B | USA |
 |
Eli Lilly and Company
LLY
|
2 B | $ 1 277.31 | 0.3 % | $ 1.15 T | USA |
 |
Lipocine
LPCN
|
-10.3 M | $ 1.43 | -0.69 % | $ 7.79 M | USA |
 |
Larimar Therapeutics
LRMR
|
-172 M | $ 2.22 | -5.53 % | $ 184 M | USA |
 |
vTv Therapeutics
VTVT
|
-32.8 M | $ 25.97 | 1.64 % | $ 103 M | USA |
 |
Moleculin Biotech
MBRX
|
-25 M | $ 6.9 | 6.12 % | $ 8.17 M | USA |
 |
MacroGenics
MGNX
|
-65.7 M | $ 2.17 | -3.56 % | $ 137 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
-62 M | $ 0.64 | -0.88 % | $ 68 M |  Canada |
 |
Merck & Co.
MRK
|
3.04 B | $ 140.44 | -3.32 % | $ 351 B | USA |
 |
Moderna
MRNA
|
-2.86 B | $ 197.65 | -1.23 % | $ 76.9 B | USA |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 3.73 | -4.97 % | $ 2.49 M | USA |
 |
Revolution Medicines
RVMD
|
-1.17 B | $ 183.82 | -1.7 % | $ 34.9 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 7.99 | -2.86 % | $ 538 B |  Britain |
 |
Alector
ALEC
|
-150 M | $ 1.83 | -0.27 % | $ 188 M | USA |
 |
Aligos Therapeutics
ALGS
|
-87.1 M | $ 4.55 | -4.81 % | $ 45 M | USA |
 |
Alkermes plc
ALKS
|
281 M | $ 44.42 | 1.8 % | $ 7.32 B | Irlanda |
 |
Allogene Therapeutics
ALLO
|
-197 M | $ 1.22 | -2.8 % | $ 269 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-2.58 M | - | -7.31 % | $ 49 M | USA |
 |
Amgen
AMGN
|
14.2 B | $ 444.7 | 1.24 % | $ 239 B | USA |
 |
Amarin Corporation plc
AMRN
|
-47.1 M | $ 12.13 | 2.88 % | $ 5.03 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
451 M | $ 21.07 | 3.39 % | $ 6.6 B | USA |
 |
AnaptysBio
ANAB
|
32.3 M | $ 48.78 | 0.1 % | $ 1.41 B | USA |
 |
Aclaris Therapeutics
ACRS
|
-75.9 M | $ 3.77 | 0.4 % | $ 462 M | USA |
 |
AC Immune SA
ACIU
|
-69.3 M | $ 2.3 | -4.96 % | $ 232 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-87 M | - | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
-21 M | $ 2.49 | 3.32 % | $ 147 M |  China |
 |
ADMA Biologics
ADMA
|
199 M | $ 11.05 | 3.46 % | $ 2.63 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.1 M | $ 26.3 | 3.1 % | $ 3.99 B | USA |
 |
Agenus
AGEN
|
-10.2 M | $ 6.19 | -2.21 % | $ 184 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-467 M | $ 36.67 | -0.91 % | $ 2.13 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 4.2 | 0.12 % | $ 805 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.51 | 4.51 % | $ 192 M | Schweiz |
 |
AbbVie
ABBV
|
15.8 B | $ 286.99 | 0.47 % | $ 508 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
106 M | $ 19.75 | 0.08 % | $ 3.33 B | USA |
 |
Artelo Biosciences
ARTL
|
-11.4 M | $ 2.32 | -10.98 % | $ 439 K | USA |
 |
Biofrontera AG
BFRA
|
-2.28 M | - | -8.24 % | $ 105 M |  Germany |